PAD blocks blood flow to the legs and feet, causing significant pain and limited mobility, potentially leading to surgery or even amputation in severe cases. Caused by the buildup of plaque and calcium within the walls of arteries, PAD occurs primarily in the legs, but can be found in vessels throughout the body. Balloon angioplasty, which involves inflating a balloon within the artery at the area of narrowing and expanding the artery to alleviate the blockage, is commonly used to treat PAD. Many patients do not respond well to angioplasty alone, with failure rates as high as 50 percent often due to hardened calcium within the wall of the artery.
“This is yet another example of the Lankenau Heart Institute’s commitment to providing cutting-edge treatment options for patients with heart and vascular conditions,” said Sarang Mangalmurti, MD, an interventional cardiologist at Bryn Mawr Hospital. “We’re thrilled to be the first in the region to offer this technology, which gives us the ability to more effectively treat hardened calcium with potentially less risk of damage or injury to the vessel.”
Shockwave Medical’s Lithoplasty system integrates angioplasty balloon catheter devices with the calcium-disrupting power of sonic pressure waves, known as lithotripsy. Each Lithoplasty catheter incorporates multiple lithotripsy emitters activated with the touch of a button after the balloon is inflated. Once activated, these emitters produce therapeutic sonic pressure waves that are inherently tissue-selective, passing through the balloon and soft vascular tissue, without damage and preferentially disrupting the calcified plaque inside the vessel wall by creating a series of micro-fractures. When the calcium has been modified, the vessel can be dilated using low pressures, thereby enabling even historically challenging PAD patients to be treated effectively with minimal injury to the vessel.
The technology is now commercially available in both the United States and Europe for the treatment of calcified plaque in peripheral arteries. On behalf of Lankenau Heart Institute, Bryn Mawr Hospital is serving as a clinical test site for Lithoplasty and will continue to participate in trials evaluating best practice usage and the effectiveness of this technology. William Gray, MD, system chief of the division of cardiovascular disease at Main Line Health and president of the Lankenau Heart Institute, is leading this important trial as its national principle investigator.
The Shockwave Medical Lithoplasty system is intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. Not for use in the coronary or cerebral vasculature.
Founded in 1985, Main Line Health is a not-for-profit health system serving Philadelphia and its western suburbs. Main Line Health's commitment—to deliver advanced medicine for treating and curing disease, playing an important role in prevention and disease management as well as training physicians and other health care providers—reflects our intent to be the region's premier choice for clinical care, research, and education. A team of more than 10,000 employees, 3,000 nurses and 2,000 physicians care for patients throughout the Main Line Health System.
At Main Line Health's core are four of the region's most respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation's premier facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.
Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region's largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care, and service, including U.S. News & World Report's Best Hospitals, System Magnet® designation; the nation's highest distinction for nursing excellence and the Mid-Atlantic Alliance for Performance Excellence (MAAPE) Excellence Award. Main Line Health is committed to creating an environment of diversity, respect, equity, and inclusion, has proudly received awards in this area and has embraced the American Hospital Association's #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education, and research to help patients stay healthy and live their best lives.
Bryn Mawr Hospital, a member of Main Line Health, is a 284-bed, not-for-profit acute care teaching hospital dedicated to helping the community stay well ahead on the path to lifelong health. Bryn Mawr Hospital has received both regional and national recognition for its excellence in providing state-of-the-art, quality care. Bryn Mawr Hospital was named among the top 10 hospitals in the Philadelphia region and the top 20 hospitals in Pennsylvania in U.S. News & World Report's Best Hospitals rankings for 2022–23. Bryn Mawr Hospital has also earned Magnet designation for the third time for its superior nursing staff. The hospital offers a full range of services, including cancer care, orthopaedic care, cardiovascular care, behavioral health, maternity care, bariatric surgery, neurovascular and a level III neonatal intensive care unit, all aided by a dedicated team of health care professionals and innovative technologies. Through Bryn Mawr Hospital's collaboration with the Jefferson Hospital for Neuroscience, the university-affiliated neurovascular center is an accredited thrombectomy-capable stroke center that offers rapid access to advanced diagnostics and treatment options for stroke care. Bryn Mawr Hospital is affiliated with the Children's Hospital of Philadelphia (CHOP) to deliver exceptional care for pediatric patients and their families, including 24/7 coverage of the pediatric emergency department, pediatric inpatient unit and level III NICU.